持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2022/03/11 | 日証協 | 106,000株 | +5.58% | 128,795株 | +15.41% | 151,824株 | -2.04% | 59,129株 | +215.41% |
2022/03/04 | 日証協 | 100,400株 | -7.28% | 111,600株 | +84.77% | 154,990株 | -4.63% | 18,747株 | +95.26% |
2022/02/25 | 日証協 | 108,280株 | -20.12% | 60,399株 | -51% | 162,516株 | -3.27% | 9,601株 | -72.65% |
2022/02/18 | 日証協 | 135,559株 | +11.02% | 123,254株 | +75.95% | 168,018株 | +13.56% | 35,100株 | +12.14% |
2022/02/10 | 日証協 | 122,105株 | -2.86% | 70,051株 | -44% | 147,961株 | -0.8% | 31,300株 | -45.84% |
2022/02/04 | 日証協 | 125,696株 | +10.94% | 125,096株 | +41.67% | 149,156株 | +32.98% | 57,790株 | +93.28% |
2022/01/28 | 日証協 | 113,305株 | -18.66% | 88,300株 | -25.42% | 112,167株 | -4.19% | 29,900株 | -40.24% |
2022/01/21 | 日証協 | 139,305株 | -1.27% | 118,400株 | -14.59% | 117,067株 | +14.84% | 50,031株 | +427.75% |
2022/01/14 | 日証協 | 141,099株 | +1.02% | 138,620株 | +21.38% | 101,936株 | +12.47% | 9,480株 | -54.65% |
2022/01/07 | 日証協 | 139,679株 | -17.49% | 114,205株 | -1.31% | 90,636株 | -23.87% | 20,902株 | -72.17% |
2021/12/30 | 日証協 | 169,280株 | 0% | 115,718株 | 0% | 119,049株 | 0% | 75,102株 | 0% |
2021/12/24 | 日証協 | 169,280株 | +14.95% | 115,718株 | +0.83% | 119,049株 | +45.85% | 75,102株 | +281.95% |
2021/12/17 | 日証協 | 147,270株 | +14.37% | 114,763株 | +147.53% | 81,627株 | -10.72% | 19,663株 | -40.11% |
2021/12/10 | 日証協 | 128,770株 | +17.56% | 46,363株 | -5.01% | 91,427株 | +47.64% | 32,832株 | +107.73% |
2021/12/03 | 日証協 | 109,539株 | +13.26% | 48,807株 | +38.11% | 61,927株 | +8.6% | 15,805株 | +269.19% |
2021/11/26 | 日証協 | 96,712株 | -11.42% | 35,340株 | -27.45% | 57,022株 | -14.28% | 4,281株 | -73.7% |
2021/11/19 | 日証協 | 109,181株 | +18.85% | 48,711株 | -15.36% | 66,521株 | +10.46% | 16,280株 | +8.51% |
2021/11/05 | 日証協 | 59,994株 | -37.49% | 8,165株 | -90.17% | 56,421株 | -40.36% | 3,500株 | -93.92% |
2021/10/29 | 日証協 | 95,974株 | +8.08% | 83,103株 | +186.93% | 94,598株 | +5.31% | 57,550株 | +48.78% |
※株式分割は考慮していませんのでご注意ください。
Page Top